Armata Pharmaceuticals, Inc. SEC filings ARMP
Armata Pharmaceuticals, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jan 27, 2004. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 23, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 20, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 20, 2026 | Jul 17, 2026 |
| 4 | Insider transaction | Jul 14, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 13, 2026 | Jul 13, 2026 |
| S-8 | Employee stock plan registration | Jul 13, 2026 | — |
| 8-K/A |
Amended current report
Officer or director change
|
Jun 24, 2026 | Apr 24, 2026 |
| 8-K |
Current report
Other events
|
Jun 23, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 11, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 13, 2026 | — |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Regulation FD disclosure
|
May 13, 2026 | May 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 7, 2026 | May 7, 2026 |
| 4 | Insider transaction | Apr 28, 2026 | Apr 24, 2026 |
| 3 | Initial insider ownership | Apr 28, 2026 | Apr 24, 2026 |
| ARS | Annual report to shareholders | Apr 27, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 27, 2026 | Apr 24, 2026 |
| 8-K |
Current report
Other events
|
Apr 2, 2026 | Apr 2, 2026 |
| 10-K | Annual report | Mar 25, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 25, 2026 | Mar 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 19, 2026 | Mar 19, 2026 |
| 4 | Insider transaction | Mar 17, 2026 | Mar 14, 2026 |
| 4 | Insider transaction | Mar 17, 2026 | Mar 14, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 4 | Insider transaction | Mar 11, 2026 | Mar 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 23, 2026 | Feb 23, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 26, 2026 | — |
| 8-K |
Current report
Material agreement
|
Jan 26, 2026 | Jan 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 13, 2026 | Jan 13, 2026 |
| 8-K |
Current report
Material agreement
|
Dec 1, 2025 | Dec 1, 2025 |
| 424B5 | Prospectus supplement | Dec 1, 2025 | — |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 22, 2025 | Oct 22, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2025 | Sep 10, 2025 |
| EFFECT | Filing | Aug 22, 2025 | — |
| CORRESP | Letter to the SEC | Aug 20, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2025 | — |
| S-8 | Employee stock plan registration | Aug 13, 2025 | — |
| S-3 | Shelf registration | Aug 13, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 12, 2025 | — |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Regulation FD disclosure
|
Aug 12, 2025 | Aug 11, 2025 |
| 4 | Insider transaction | Jul 14, 2025 | Jul 10, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 19, 2025 | May 19, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| 8-K |
Current report
Other events
|
May 1, 2025 | May 1, 2025 |
| ARS | Annual report to shareholders | Apr 28, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Apr 25, 2025 | Jul 10, 2024 |
| 4 | Insider transaction | Apr 25, 2025 | Mar 14, 2025 |
| 3/A | Ownership document | Apr 25, 2025 | Jun 19, 2024 |
| 8-K |
Current report
Other events
|
Apr 2, 2025 | Apr 2, 2025 |
| 10-K | Annual report | Mar 21, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2025 | Mar 20, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 12, 2025 | — |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Mar 12, 2025 | Mar 12, 2025 |
| 4 | Insider transaction | Feb 7, 2025 | Feb 5, 2025 |
| 4 | Insider transaction | Feb 7, 2025 | Feb 5, 2025 |
| 4 | Insider transaction | Feb 7, 2025 | Feb 5, 2025 |
| 4 | Insider transaction | Feb 7, 2025 | Feb 5, 2025 |
| 4 | Insider transaction | Feb 7, 2025 | Feb 5, 2025 |
| 4 | Insider transaction | Feb 7, 2025 | Feb 5, 2025 |
| 4 | Insider transaction | Feb 7, 2025 | Feb 5, 2025 |
| 4 | Insider transaction | Feb 7, 2025 | Feb 5, 2025 |
| 4 | Insider transaction | Feb 7, 2025 | Feb 5, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 19, 2024 | Dec 19, 2024 |
| 8-K |
Current report
Officer or director change
|
Dec 4, 2024 | Dec 2, 2024 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Nov 15, 2024 | Nov 12, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Nov 14, 2024 | — |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 12, 2024 | Nov 12, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 3, 2024 | Sep 30, 2024 |
| 4 | Insider transaction | Oct 3, 2024 | Oct 2, 2024 |
| 8-K |
Current report
Officer or director change
|
Sep 26, 2024 | Sep 22, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 26, 2024 | Aug 26, 2024 |
| 3 | Initial insider ownership | Aug 19, 2024 | Aug 16, 2024 |
| 8-K |
Current report
Officer or director change
|
Aug 15, 2024 | Jul 31, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Jul 25, 2024 | Jul 22, 2024 |
| 3 | Initial insider ownership | Jun 28, 2024 | Jun 19, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2024 | Jun 12, 2024 |
| 10-Q | Quarterly report | May 7, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 7, 2024 | May 7, 2024 |
| ARS | Annual report to shareholders | Apr 29, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 12, 2024 |
| 8-K | Current report | Mar 22, 2024 | Mar 22, 2024 |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2024 | Mar 21, 2024 |
| 4 | Insider transaction | Mar 18, 2024 | Mar 14, 2024 |
| 4 | Insider transaction | Mar 18, 2024 | Mar 14, 2024 |
| 4 | Insider transaction | Mar 18, 2024 | Mar 14, 2024 |
| 4 | Insider transaction | Mar 18, 2024 | Mar 14, 2024 |
| 4 | Insider transaction | Mar 18, 2024 | Mar 14, 2024 |
| 4 | Insider transaction | Mar 18, 2024 | Mar 14, 2024 |
| 4 | Insider transaction | Mar 18, 2024 | Mar 14, 2024 |
| 4 | Insider transaction | Mar 18, 2024 | Mar 14, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Mar 4, 2024 | — |
| 8-K |
Current report
Material agreement, New debt
|
Mar 4, 2024 | Mar 4, 2024 |
| S-8 | Employee stock plan registration | Jan 23, 2024 | — |
| 4 | Insider transaction | Dec 26, 2023 | Dec 21, 2023 |
| 4 | Insider transaction | Dec 26, 2023 | Dec 21, 2023 |
| 4 | Insider transaction | Dec 26, 2023 | Dec 21, 2023 |
| 4 | Insider transaction | Dec 26, 2023 | Dec 21, 2023 |
| 4 | Insider transaction | Dec 26, 2023 | Dec 21, 2023 |
| 4 | Insider transaction | Dec 26, 2023 | Dec 21, 2023 |
| 4 | Insider transaction | Dec 26, 2023 | Dec 21, 2023 |
| 4 | Insider transaction | Dec 26, 2023 | Dec 21, 2023 |
| S-8 | Employee stock plan registration | Nov 15, 2023 | — |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2023 | Nov 14, 2023 |
| UPLOAD | Letter from the SEC | Nov 13, 2023 | — |
| CORRESP | Letter to the SEC | Nov 7, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 26, 2023 | — |
| 3 | Initial insider ownership | Sep 22, 2023 | Sep 15, 2023 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 20, 2023 | Sep 14, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2023 | Aug 14, 2023 |
| ARS | Annual report to shareholders | Aug 3, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Aug 3, 2023 | — |
| DEF 14A | Proxy statement | Aug 3, 2023 | Sep 14, 2023 |
| PRE 14A | Preliminary proxy statement | Jul 24, 2023 | Sep 14, 2023 |
| 8-K |
Current report
Officer or director change
|
Jul 19, 2023 | Jul 10, 2023 |
| 3 | Initial insider ownership | Jul 19, 2023 | Jul 10, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Jul 11, 2023 | — |
| 8-K |
Current report
Material agreement, New debt, Officer or director change, Other events
|
Jul 11, 2023 | Jul 10, 2023 |
| 8-K |
Current report
Results of operations, Other events
|
Jun 27, 2023 | Jun 27, 2023 |
| 8-K |
Current report
Results of operations
|
May 12, 2023 | May 11, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | May 8, 2023 | May 2, 2023 |
| 8-K |
Current report
Officer or director change
|
May 5, 2023 | May 1, 2023 |
| EFFECT | Filing | Apr 6, 2023 | — |
| 424B3 | Prospectus | Apr 6, 2023 | — |
| CORRESP | Letter to the SEC | Apr 5, 2023 | — |
| S-3/A | Form s-3/a | Mar 28, 2023 | — |
| 8-K |
Current report
Results of operations
|
Mar 16, 2023 | Mar 16, 2023 |
| 10-K | Annual report | Mar 16, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 6, 2023 | Mar 6, 2023 |
| UPLOAD | Letter from the SEC | Feb 17, 2023 | — |
| S-3 | Shelf registration | Feb 13, 2023 | — |
| 3 | Initial insider ownership | Feb 7, 2023 | Jul 1, 2022 |
| 4 | Insider transaction | Jan 12, 2023 | Jan 10, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Jan 10, 2023 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jan 10, 2023 | Jan 10, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 19, 2022 | Dec 14, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Nov 18, 2022 | Nov 16, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2022 | Nov 9, 2022 |
| 10-Q | Quarterly report | Nov 9, 2022 | Sep 30, 2022 |
| DEF 14A | Proxy statement | Oct 17, 2022 | Nov 16, 2022 |
| 8-K |
Current report
Results of operations, Other events
|
Sep 20, 2022 | Sep 20, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 424B3 | Prospectus | Jun 1, 2022 | — |
| EFFECT | Filing | May 31, 2022 | — |
| CORRESP | Letter to the SEC | May 26, 2022 | — |
| S-3/A | Form s-3/a | May 24, 2022 | — |
| UPLOAD | Letter from the SEC | May 19, 2022 | — |
| S-3 | Shelf registration | May 16, 2022 | — |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 4 | Insider transaction | Apr 15, 2022 | Apr 13, 2022 |
| 4 | Insider transaction | Apr 15, 2022 | Apr 13, 2022 |
| 4 | Insider transaction | Apr 15, 2022 | Apr 13, 2022 |
| 4 | Insider transaction | Apr 15, 2022 | Apr 13, 2022 |
| 4 | Insider transaction | Apr 15, 2022 | Apr 13, 2022 |
| 4 | Insider transaction | Apr 15, 2022 | Apr 13, 2022 |
| 4 | Insider transaction | Apr 15, 2022 | Apr 13, 2022 |
| 4 | Insider transaction | Apr 15, 2022 | Apr 13, 2022 |
| 4 | Insider transaction | Apr 15, 2022 | Apr 13, 2022 |
| EFFECT | Filing | Apr 6, 2022 | — |
| 424B3 | Prospectus | Apr 6, 2022 | — |
| CORRESP | Letter to the SEC | Apr 5, 2022 | — |
| 4 | Insider transaction | Apr 1, 2022 | Mar 31, 2022 |
| SC 13D/A | Amended ownership over 5% (active) | Apr 1, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2022 | — |
| 8-K |
Current report
Unregistered share sale, Shareholder vote results, Other events
|
Mar 31, 2022 | Mar 30, 2022 |
| S-3 | Shelf registration | Mar 29, 2022 | — |
| 8-K |
Current report
Officer or director change
|
Mar 28, 2022 | Mar 25, 2022 |
| 10-K | Annual report | Mar 17, 2022 | Dec 31, 2021 |
| DEF 14A | Proxy statement | Mar 9, 2022 | Mar 30, 2022 |
| PRE 14A | Preliminary proxy statement | Feb 24, 2022 | Mar 30, 2022 |
| 4 | Insider transaction | Feb 11, 2022 | Feb 9, 2022 |
| SC 13D/A | Amended ownership over 5% (active) | Feb 11, 2022 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Feb 11, 2022 | Feb 9, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 5, 2022 | Jan 5, 2022 |
| 10-Q | Quarterly report | Nov 10, 2021 | Sep 30, 2021 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ARMP (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- WA
- Headquarters
- Los Angeles, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 921114
- Former names
- AmpliPhi Biosciences Corp (until May 8, 2019); TARGETED GENETICS CORP /WA/ (until Feb 11, 2011)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.